{"id":"NCT03347396","sponsor":"Bioverativ, a Sanofi company","briefTitle":"A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study)","officialTitle":"A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-05","primaryCompletion":"2021-10-05","completion":"2021-10-05","firstPosted":"2017-11-20","resultsPosted":"2022-10-31","lastUpdate":"2022-10-31"},"enrollment":24,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Agglutinin Disease, Cold"],"interventions":[{"type":"DRUG","name":"BIVV009","otherNames":["Sutimlimab"]}],"arms":[{"label":"BIVV009","type":"EXPERIMENTAL"}],"summary":"The purpose of Part A was to determine whether sutimlimab administration resulted in a greater than or equal to (\\>=) 2 grams per deciliter (g/dL) increase in hemoglobin (Hgb) levels or increased Hgb to \\>= 12 g/dL and obviated the need for blood transfusion during treatment in participants with primary cold agglutinin disease (CAD) who had a recent history of blood transfusion. The purpose of Part B was to evaluate the long-term safety and tolerability of sutimlimab in participants with CAD.","primaryOutcome":{"measure":"Part A: Percentage of Participants With Response to Treatment","timeFrame":"From Week 5 through Week 26","effectByArm":[{"arm":"BIVV009","deltaMin":54.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":49,"countries":["United States","Australia","Austria","Belgium","Canada","France","Germany","Israel","Italy","Japan","Netherlands","Norway","Spain","United Kingdom"]},"refs":{"pmids":["37459203","37246953","35999387","34778998","33826820"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":17},"commonTop":["Anaemia","Diarrhoea","Fatigue","Nausea","Pyrexia"]}}